248 related articles for article (PubMed ID: 23064619)
1. Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma.
Thunnissen E; Boers E; Heideman DA; Grünberg K; Kuik DJ; Noorduin A; van Oosterhout M; Pronk D; Seldenrijk C; Sietsma H; Smit EF; van Suylen R; von der Thusen J; Vrugt B; Wiersma A; Witte BI; den Bakker M
Virchows Arch; 2012 Dec; 461(6):629-38. PubMed ID: 23064619
[TBL] [Abstract][Full Text] [Related]
2. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
[TBL] [Abstract][Full Text] [Related]
3. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer.
Lozano MD; Labiano T; Echeveste J; Gurpide A; Martín-Algarra S; Zhang G; Sharma A; Palma JF
Cancer Cytopathol; 2015 Apr; 123(4):230-6. PubMed ID: 25529460
[TBL] [Abstract][Full Text] [Related]
4. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.
Rekhtman N; Brandt SM; Sigel CS; Friedlander MA; Riely GJ; Travis WD; Zakowski MF; Moreira AL
J Thorac Oncol; 2011 Mar; 6(3):451-8. PubMed ID: 21266922
[TBL] [Abstract][Full Text] [Related]
5. Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?
Vincenten JP; Smit EF; Grünberg K; Postmus PE; Snijders PJ; Witte BI; Heideman DA; Thunnissen E
Lung Cancer; 2015 Jul; 89(1):19-26. PubMed ID: 25982011
[TBL] [Abstract][Full Text] [Related]
6. Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.
Carneiro JG; Couto PG; Bastos-Rodrigues L; Bicalho MA; Vidigal PV; Vilhena A; Amaral NF; Bale AE; Friedman E; De Marco L
Genet Res (Camb); 2014; 96():e002. PubMed ID: 24594201
[TBL] [Abstract][Full Text] [Related]
7. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.
Santis G; Angell R; Nickless G; Quinn A; Herbert A; Cane P; Spicer J; Breen R; McLean E; Tobal K
PLoS One; 2011; 6(9):e25191. PubMed ID: 21949883
[TBL] [Abstract][Full Text] [Related]
8. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
Rekhtman N; Paik PK; Arcila ME; Tafe LJ; Oxnard GR; Moreira AL; Travis WD; Zakowski MF; Kris MG; Ladanyi M
Clin Cancer Res; 2012 Feb; 18(4):1167-76. PubMed ID: 22228640
[TBL] [Abstract][Full Text] [Related]
9. The Value of Cytokeratin 5/6, p63 and Thyroid Transcription Factor-1 in Adenocarcinoma, Squamous Cell Carcinoma and Non-Small-Cell Lung Cancer of the Lung.
Argon A; Nart D; Veral A
Turk Patoloji Derg; 2015; 31(2):81-8. PubMed ID: 25944390
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens.
Rekhtman N; Ang DC; Sima CS; Travis WD; Moreira AL
Mod Pathol; 2011 Oct; 24(10):1348-59. PubMed ID: 21623384
[TBL] [Abstract][Full Text] [Related]
11. The role of the cytopathologist in subtyping and epidermal growth factor receptor testing in non-small cell lung cancer: An institutional experience.
Sekar A; Gupta N; Rajwanshi A; Chaturvedi R; Singh N; Lal A
Cytopathology; 2017 Oct; 28(5):371-377. PubMed ID: 28730709
[TBL] [Abstract][Full Text] [Related]
12. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.
Mukhopadhyay S; Katzenstein AL
Am J Surg Pathol; 2011 Jan; 35(1):15-25. PubMed ID: 21164283
[TBL] [Abstract][Full Text] [Related]
13. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
[TBL] [Abstract][Full Text] [Related]
14. The utility of TTF-1, napsin A, CK5 and p63 staining in the sub-classification of non-small cell carcinoma of the lung.
van Zyl A; Schubert PT; Koegelenberg CFN
Cytopathology; 2019 Nov; 30(6):586-591. PubMed ID: 31206846
[TBL] [Abstract][Full Text] [Related]
15. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
16. [Feasibility of assessing EGFR mutation and others using samples obtained by EBUS transbronchial needle aspiration].
Boulanger S; Delattre C; Descarpentries C; Escande F; Bouchindhomme B; Copin MC; Dhalluin X; Scherpereel A; Ramon PP; Cortot A; Fournier C
Rev Mal Respir; 2013 May; 30(5):351-6. PubMed ID: 23746811
[TBL] [Abstract][Full Text] [Related]
17. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.
Beau-Faller M; Blons H; Domerg C; Gajda D; Richard N; Escande F; Solassol J; Denis MG; Cayre A; Nanni-Metellus I; Olschwang S; Lizard S; Piard F; Pretet JL; de Fraipont F; Bièche I; de Cremoux P; Rouquette I; Bringuier PP; Mosser J; Legrain M; Voegeli AC; Saulnier P; Morin F; Pignon JP; Zalcman G; Cadranel J
J Mol Diagn; 2014 Jan; 16(1):45-55. PubMed ID: 24183959
[TBL] [Abstract][Full Text] [Related]
18. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.
Do H; Krypuy M; Mitchell PL; Fox SB; Dobrovic A
BMC Cancer; 2008 May; 8():142. PubMed ID: 18495026
[TBL] [Abstract][Full Text] [Related]
19. Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer.
Bozzetti C; Naldi N; Nizzoli R; Azzoni C; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Gasparro D; Majori M; De Filippo M; Ardizzoni A
Lung Cancer; 2013 Apr; 80(1):35-8. PubMed ID: 23352033
[TBL] [Abstract][Full Text] [Related]
20. Adequacy of CT-guided biopsies with histomolecular subtyping of pulmonary adenocarcinomas: influence of ATS/ERS/IASLC guidelines.
Ferretti GR; Busser B; de Fraipont F; Reymond E; McLeer-Florin A; Mescam-Mancini L; Moro-Sibilot D; Brambilla E; Lantuejoul S
Lung Cancer; 2013 Oct; 82(1):69-75. PubMed ID: 23927885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
